Human skin replacement - Amarantus Bioscience

Drug Profile

Human skin replacement - Amarantus Bioscience

Alternative Names: Cultured skin substitute - Amarantus Bioscience; Engineered skin substitute - Amarantus Bioscience; ESS-W; PermaDerm

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Lonza
  • Developer Amarantus Bioscience Holdings
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Burns
  • Clinical Phase Unknown Nevus

Most Recent Events

  • 13 Sep 2016 Phase-II clinical trials in Burns in USA (Topical)
  • 08 Aug 2016 Clinical trials in Burns (In children) in USA (Topical) prior to August 2016
  • 08 Aug 2016 Positive efficacy data from a compassionate use clinical trial in Burns released by Amarantus BioScience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top